Elixirr International plc (ELIX) — Investment Research Note

Executive summary

Elixirr is a UK-listed global "challenger consultancy" that has grown revenue at a ~38% CAGR since 2020 through a four-pillar strategy of stretching/promoting/hiring Partners and rolling up boutique firms (nine acquisitions since IPO). The trajectory has been consistent double-digit growth at 28-31% adjusted EBITDA margins, though H1 26 (Sep 21, 2026) showed a marked slowdown in organic growth to just 5% at constant currency, with the balance sheet having flipped from £20m net cash (FY22) to £56.5m net debt on M&A funding. The single most important valuation point is that after a >40% drawdown from 12-month highs, ELIX now trades at roughly 7x FY26 adjusted diluted EPS and ~6.5x EV/EBITDA — cheap absolute levels for a business still guiding to EBITDA in line with expectations and growing AI-related revenue by 185%.

Fair value estimate

• Methodology: Blended P/E multiple on FY26 adjusted diluted EPS + cross-check on EV/EBITDA
• Key assumptions:
  • FY26 adjusted diluted EPS ~65-72p (H1 26 delivered 34.2p; H2 typically stronger seasonally per management commentary)
  • FY26 adjusted EBITDA ~£55-58m (H1 £27.6m at 31% margin; management confirmed FY26 EBITDA "in line with market expectations")
  • Fair P/E of 11-14x reflecting programmatic M&A model, 25%+ headline growth, but slowing organic and weaker balance sheet
  • Peer comparables: IT services and mid-cap consultancies typically trade 12-18x forward P/E; Elixirr previously commanded a premium multiple that has now compressed
• Fair value range: 750p – 950p per share
• Implied market cap range: £372m – £471m (using ~49.6m shares)
• Current market cap: £308.3m
• Absolute upside: +51% to midpoint (850p), range +51% to +91%

Sector context

• Sector classification confirmed: Industrials / Industrial Goods and Services (ICB). More precisely, this is "Professional Business Services" — closer to IT services/consulting than industrials in the traditional sense.
• Quality/growth profile is above typical peers: 30% adjusted EBITDA margin vs. Big-4 consulting norms of 15-20%; 25% headline revenue growth vs. mid-single-digit industry growth; leverage now in line with peers.
• Listed peers: Alpha Financial Markets Consulting (AFM), FDM Group, and internationally Accenture and Capgemini. Alpha and FDM are the closest UK-listed comparables in scale and business model.

Investment thesis (3 bullets)

1. Genuine AI-implementation exposure with rapid revenue conversion. AI-related revenue grew 185% to £8.1m in H1 26 and 260%+ in FY 25, with management describing the firm as an "AI enabler" positioned to capture the $200bn agentic-AI tech services opportunity 2026-09-21 interim; 2026-08-03 trading update. Elixirr AI (formerly Responsum) and Elixirr Digital (formerly iOLAP) provide the technical capabilities.
2. Compelling entry point after >40% drawdown. Trading at ~7x FY26 adjusted diluted EPS with the founder still leading, 30%+ EBITDA margins, and a 20% CAGR dividend growth trajectory (17.8p → 22.6p implied). H1 26 EPS growth of +18% is not reflected in the current 498p print 2026-09-21 interim.
3. Programmatic M&A model has demonstrable payback. Nine acquisitions since 2020 IPO with cross-sell revenue up 27% YoY to £19m in H1 26. TRC (Sep 2025) already achieved its full FY25 earnout in one quarter 2026-09-21 interim.

Key risks (3 bullets)

1. Organic growth is decelerating sharply. Constant currency organic revenue growth was just 5% in H1 26 (vs. 17% in H1 25), meaning the 25% headline growth is largely M&A-driven 2026-09-21 interim. This is the number one bear case and suggests the growth story is starting to depend on further acquisitions.
2. Balance sheet has weakened materially. Net debt rose from £6.8m at H1 25 to £56.5m at H1 26 (leverage ratio 1.1x). Free cash flow collapsed 78% to £1.8m in H1 26 due to acquisition-related working capital consumption and Kvadrant/TRC earnout payments 2026-09-21 interim. Continued acquisition-led growth requires access to capital.
3. Repriced options and governance signals. In H1 26, 4.4m options with exercise prices above £6.45 were repriced to £6.45, indicating share price weakness relative to option grants 2026-09-21 interim. Loans to shareholders of £9.5m and related-party transactions with CEO Stephen Newton's private businesses (Cape Point Wine, Aviation E LLP) are minor but worth flagging.

Operating leverage

Consulting is fundamentally a people-cost business (cost of sales was 66% of revenue in H1 26), so pure operating leverage is moderate rather than high. However, there are real signs of scale economics: administrative expenses only grew 5% in H1 26 vs. revenue growth of 25%, driving 100bps of EBITDA margin expansion to 31%. Revenue per Partner has grown from ~£3.15m (FY21) to ~£4.1m (FY24), reflecting genuine leverage on the Partner base as central capabilities (marketing, Centre of Excellence in Croatia/South Africa, back-office) support more revenue 2025-04-28 final results. On a 10-20% revenue beat above plan, incremental drop-through would likely be at 40-50% contribution margin (given ~34% gross margin and mostly fixed admin costs), so operating profit could rise 30-50% on a 15% revenue beat — meaningful but not multi-baggering. The bigger operating leverage comes indirectly through the "capability platform" — cross-selling data/AI/creative into existing consulting relationships extends deal sizes without proportional cost.

Value-trap signals

• Decelerating organic revenue growth: 5% constant currency in H1 26 vs. 17% in H1 25.
• Sharply reduced free cash flow: £1.8m in H1 26 vs. £7.9m in H1 25 (-78%).
• Rising net debt with acquisition-dependent growth: £56.5m net debt vs. £6.8m a year ago; borrowings expanded significantly to fund Kvadrant and TRC earnout.
• Option repricing in H1 26 — 4.4m options reset to £6.45.
• FY26 guidance only "in line" despite strong H1 headline growth — the 20% one-day share price drop on results day suggests the market read this as effectively a downgrade.
• Related-party transactions with founder-CEO's other businesses (minor but persistent).

Earnings vs. expectations

Elixirr had a strong track record of meeting or beating expectations from IPO through FY24:

• FY22: Revenue £70.7m (guidance £70-75m), EBITDA £20.5m (above £20m guidance) — beat
• FY23: Revenue £85.9m (guidance £85-90m), EBITDA margin 30% (guidance 28-30%) — met/beat
• FY24: Revenue £111.3m (above £108-111m guidance), EBITDA margin 28% (in middle of 27-29%) — beat
• FY25: Trading update Jan 2026 indicated revenue expected to "meet or exceed" £149m, EBITDA margin "meet or exceed 28.1-29.2%" — beat
• FY26 outlook (Sep 2026): EBITDA "in line" and revenue "broadly in line" with market expectations — this is the first time in the covered period that guidance has been effectively unchanged rather than upgraded, which likely explains the 19.9% price drop on 2026-09-21.

The pattern is consistent beats with a notable "in line" print in the most recent update, suggesting the momentum has softened.

Conviction

Conviction: 3 (moderate)

Factors that anchor confidence:

• Consistent, clean disclosure across all filings with detailed segment/APM reconciliations.
• Strong track record of meeting guidance (18+ consecutive quarters).
• Two independent valuation methods (P/E and EV/EBITDA) converge on a similar fair-value range.

Factors that limit confidence:

• The organic growth deceleration to 5% is a genuine unknown — could be macro-driven (as management implied by referencing FX/USD weakness) or a structural slowdown. Hard to distinguish from these filings alone.
• Balance sheet transition from net cash to meaningful net debt over one year is unusually rapid for a services business; the sustainability of continued M&A-led growth is uncertain.
• Consulting is inherently harder to value than SaaS given human capital dependence.